Etizolam (Depas) is a thienotriazolodiazepine derivative, similar in structure to brotizolam, that has been in clinical use in certain Asian and European countries since 1983 as a sedative-hypnotic drug. It has gathered some popularity on the new psychoactive substance (NPS) market in the UK and Europe. Etizolam is unlicensed in the UK although used as a prescribed medication in other countries such as India, Italy and Japan. A 1 mg tablet is equivalent to a 10 mg diazepam (Valium) tablet.
The adverse effects of etizolam therapy include confusion, disorientation, ataxia, slurred speech and delerium.
None required.
Measured by LC-MS/MS
Please contact laboratory for interpretation.
Copyright heftpathology 2013, 2014, 2015, 2016, 2017, 2018
HTA licence number is 12366
Protection of Personal Information – Laboratory Medicine comply with the Trust Data Protection Policy and have procedures in place to allow the Directorate and it’s employees to comply with the Data Protection Act 1998 and associated best practice and guidance.
The Trust Laboratories at Heartlands Hospital, Good Hope Hospital and Solihull Hospital were awarded UKAS (United Kingdom Accreditation Service) accreditation to the internationally recognised ISO 15189 standard in May 2015. For a list of accredited tests and other information please visit the test database http://www.heftpathology.com/frontpage/test-database.html.
Tests not appearing on this scope are either under consideration or in the process of accreditation and so currently remain outside of our scope of accreditation. However, these tests have been validated to the same high standard as accredited tests and are performed by the same trained and competent staff.
For further information contact Louise Fallon, Quality Manager, 0121 424 1235